8-K: Catheter Precision Reports Q2 2024 Results, Highlights Initial LockeT Sales

Catheter Precision announced its Q2 2024 financial results, including the first commercial sales of its LockeT device and progress in hospital evaluations for both LockeT and VIVO products.

Summary

• Catheter Precision released its Q2 2024 financial and operational report, highlighting the first commercial sales of the LockeT device in the US.
• The company has made 14 new sales and clinical hires who are in various stages of training.
• 23 US hospitals have scheduled evaluations for LockeT and 10 for VIVO, exceeding initial projections.
• VIVO product evaluation has commenced at a large volume center in Italy.
• The VIVO EU Registry was completed in June 2024.
• Total assets as of June 30, 2024, were $26 million.
• The company's cash position was $16 thousand on June 30, 2024, and increased to $330 thousand by August 12, 2024.
• Total revenue for the three months ended June 30, 2024, was $93 thousand, and $175 thousand for the six months ended June 30, 2024.
• Shareholders' equity was $14.3 million as of June 30, 2024.
• The net loss for the three months ended June 30, 2024, was ($4.2) million, and ($6.9) million for the six months ended June 30, 2024.
• LockeT sales were $38 thousand for both the three and six months ended June 30, 2024.

Sentiment

Score: 4

Explanation: While the company has achieved some operational milestones, the very low cash position, significant net losses, and dependence on additional financing create a negative sentiment. The first commercial sales of LockeT are a positive, but the financial situation is concerning.

Positives

• The company successfully launched commercial sales of LockeT in the US.
• There is strong hospital interest in both LockeT and VIVO, exceeding initial expectations.
• The company has expanded its sales and clinical team to support growth.
• The VIVO EU Registry was completed, marking a regulatory milestone.
• The company's cash position improved significantly between June 30 and August 12, 2024.

Negatives

• The company reported a net loss of ($4.2) million for the three months ended June 30, 2024, and ($6.9) million for the six months ended June 30, 2024.
• Total revenue for the quarter was only $93 thousand.
• The company had a very low cash balance of $16 thousand at the end of June 2024.

Risks

• The company's ability to continue operations is dependent on securing additional financing or a strategic transaction.
• The company needs to achieve product expansion and growth goals to reach profitability.
• The company's research and development and commercialization efforts may depend on agreements with corporate collaborators.
• Joint marketing agreements may reduce revenues from product sales.
• Royalty agreements with respect to the LockeT device will reduce future profits.
• The company has identified material weaknesses in its internal controls and disclosure controls.
• The company's revenues depend on customer reimbursement from private insurers and government programs.
• The company faces strong competition in the medical device industry.
• The company's operations are subject to pervasive and continuing FDA regulatory requirements.
• Changes in trade policies and tariffs could negatively impact the company's revenues and operating results.
• The COVID-19 pandemic, supply chain disruptions, and stock market volatility pose additional risks.

Future Outlook

The company's future performance depends on its ability to secure additional financing, achieve product expansion and growth goals, and navigate various market and regulatory risks. The company is focused on expanding its sales strategy and marketing VIVO in new US territories.

Management Comments

• David Jenkins, CEO, stated that the company focused on acquiring additional talent for the US to support the new sales strategy under the new Chief Commercial Officer, Marie-Claude Jacques.
• David Jenkins also noted that the company recognized initial revenue for LockeT and continued marketing VIVO in new US territories.

Industry Context

Catheter Precision operates in the competitive medical device industry, specifically in the growing field of cardiac electrophysiology. The company's focus on innovative solutions like VIVO and LockeT positions it to address the needs of physicians in this area. The company is competing with larger, more established companies in the space.

Comparison to Industry Standards

• The company's revenue of $93 thousand for the quarter is very low compared to established medical device companies, which often report revenues in the millions or billions.
• The net loss of $4.2 million for the quarter is significant, indicating that the company is still in a high-growth, high-burn phase.
• The cash position of $16 thousand at the end of June is extremely low, highlighting the company's urgent need for additional funding.
• Companies like Boston Scientific and Medtronic, which are major players in the cardiac electrophysiology market, have significantly larger revenues and resources.
• The company's early stage of commercialization and low revenue is comparable to other early-stage medical device companies, but the low cash position is a concern.

Stakeholder Impact

• Shareholders are impacted by the company's significant net losses and the need for additional financing.
• Employees are impacted by the company's financial instability and potential need for restructuring.
• Customers (hospitals and physicians) are impacted by the company's ability to continue to supply and support its products.
• Suppliers are impacted by the company's financial instability and potential inability to pay for components.
• Creditors are impacted by the company's financial instability and potential inability to repay debts.

Next Steps

• The company will continue to focus on its new sales strategy and marketing VIVO in new US territories.
• The company will attend the Kansas City Heart Rhythm Society Conference (KCHRS) in Kansas City on August 17 and 18, 2024.
• The company needs to secure additional financing to continue operations.

Key Dates

Keywords

Catheter Precision, LockeT, VIVO, cardiac electrophysiology, medical device, sales, financial results, hospital evaluations, revenue, net loss